🏛️ Verified NIH Record • Updated 2025-06-10

Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry (NCT04076813)

🔵 Active, Not Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Chiesi USA, Inc.

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this registry is to address optimal platelet inhibition during the early management of MI patients prior to coronary angiography or CABG.

Who can join: Review the eligibility criteria below.

Location: The Regents of the University of California on behalf of its San Diego campus — La Jolla, California

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (11 Sites)

  • The Regents of the University of California on behalf of its San Diego campus — La Jolla, California
  • Christiana Care Health Services, Inc. — Newark, Delaware
  • University of Florida — Gainesville, Florida
  • Kootenai Hospital District dba Kootenai Health — Coeur d'Alene, Idaho
  • MedStar Health Research Institute, Inc. — Hyattsville, Maryland
  • The Brigham and Women's Hospital, Inc. — Boston, Massachusetts
  • Henry Ford Health System — Detroit, Michigan
  • Washington University — St Louis, Missouri
  • The Trustees of Columbia University in the City of New York — New York, New York
  • Duke University — Durham, North Carolina
  • Vanderbilt University Medical Center — Nashville, Tennessee

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗